急性髓系白血病骨髓抑制期流式细胞术微小残留病对预后的意义
回顾性分析85例初诊急性髓系白血病(非急性早幼粒细胞白血病)患者诱导化疗后骨髓抑制期八色多参数流式细胞术检测的微小残留病(MRD),以2.305%为界,MRD<2.305%组1个疗程完全缓解率显著高于MRD≥2.305%组,但两组无复发生存率和总生存率无显著差异;多因素分析显示该MRD界值是1个疗程诱导疗效的唯一独立预后因素。
要点
- 骨髓抑制期MRD以2.305%为界,可预测首次诱导化疗后的完全缓解。
- MRD<2.305%组1个疗程完全缓解率为96.6%(56/58),高于MRD≥2.305%组的51.9%(14/27)。
- 两组无复发生存率和总生存率差异均无统计学意义。
核心结论
- 急性髓系白血病患者诱导化疗后骨髓抑制期,采用多参数流式细胞术检测的骨髓微小残留病以2.305%为界能够预测诱导化疗疗效。
研究设计与样本
- 回顾性分析85例初诊急性髓系白血病(非急性早幼粒细胞白血病)患者,采用八色多参数流式细胞术检测诱导化疗后骨髓抑制期骨髓微小残留病,并分析其与疗效及预后的关系。
主要发现
- 85例患者中男42例(49.4%)、女43例(50.6%),中位年龄35(15~54)岁,骨髓抑制期微小残留病中位数为0.58%(0~81.11%),1个疗程诱导治疗后完全缓解70例(82.4%)。
- 受试者工作特征曲线分析得到微小残留病阈值为2.305%(敏感度=0.867,特异度=0.800)。
- 微小残留病<2.305%组1个疗程完全缓解率为96.6%(56/58),高于微小残留病≥2.305%组的51.9%(14/27),差异有统计学意义(χ²=22.348,P<0.001)。
- 两组无复发生存率差异无统计学意义(χ²=1.08,P=0.299),总生存率差异无统计学意义(χ²=0.42,P=0.516)。
- 多因素分析显示,以2.305%为界的微小残留病是第1个疗程诱导疗效的唯一独立预后因素(OR=21.560,95%CI 4.129~112.579,P<0.001)。
关键数值与推荐
- 微小残留病阈值2.305%(敏感度=0.867,特异度=0.800)。
- 微小残留病<2.305%组1个疗程完全缓解率96.6%(56/58),微小残留病≥2.305%组51.9%(14/27)。
- 以2.305%为界的微小残留病是第1个疗程诱导疗效的唯一独立预后因素(OR=21.560,95%CI 4.129~112.579,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the impact of minimal residual disease (MRD) by multiparameter flow cytometry (MPFC) during aplasia on efficacy and prognosis of de novo acute myeloid leukemia (AML) (non M(3)) patients. Methods: The MRD data by 8-color MPFC during aplasia (day 14-15 of induction therapy) in 85 de novo AML (non M(3)) patients and the MRD impact on efficacy and prognosis were retrospectively analyzed. Results: Data of 85 patients, including 42 males (49.4%) and 43 females (50.6%) , were collected, with a median age of 35 (15-54) years. The median MRD by MPFC during aplasia was 0.58% (0-81.11%) , and 70 (82.4%) patients achieved complete remission (CR) after first induction chemotherapy. The cutoff of MRD by receiver operating characteristic (ROC) analysis was 2.305% (Se= 0.867, Sp=0.800) . The CR rate after one course was significantly higher in patients with MRD<2.305% [96.6% (56/58) ]than in patients with MRD≥2.305%[51.9% (14/27) ] (χ(2)=22.348, P<0.001) ; no significant difference with respect to relapse-free survival rate (χ(2)=1.08, P=0.299) or overall survival rate (χ(2)=0.42, P=0.516) could be demonstrated for the comparison of the two groups. Multivariates analysis showed MRD divided by 2.305% was the only independent prognostic factor for CR after one course (OR= 21.560, 95% CI 4.129-112.579, P<0.001) . Conclusion: Flow cytometric MRD divided by 2.305% during aplasia could be a predictor of efficacy after first induction therapy in AML patients. 目的: 探讨急性髓系白血病(AML)患者诱导化疗后骨髓抑制期,采用多参数流式细胞术(MPFC)检测的骨髓微小残留病(MRD)在疗效判断及预后中的价值。 方法: 回顾性分析85例初诊并于诱导化疗后第7~8天采用八色MPFC检测了骨髓MRD的AML(非急性早幼粒细胞白血病)患者临床资料,对其与疗效及预后的关系进行统计学分析。 结果: 在85例患者中,男42例(49.4%),女43例(50.6%),中位年龄35(15~54)岁,诱导化疗后第7~8天MRD中位数0.58%(0~81.11%),1个疗程诱导治疗后完全缓解(CR)患者70例(82.4%)。根据受试者工作特征曲线(ROC曲线)得到MRD的阈值为2.305%(Se=0.867,Sp=0.800)。MRD<2.305%的患者1个疗程CR率为96.6%(56/58),MRD≥ 2.305%的患者1个疗程CR率为51.9%(14/27),两组CR率差异有统计学意义(χ(2)=22.348,P<0.001);两组无复发生存率差异无统计学意义(χ(2)=1.08,P=0.299);两组总生存率差异无统计学意义(χ(2)=0.42,P=0.516)。多因素分析结果显示,以2.305%为界的MRD(OR=21.560,95% CI 4.129~ 112.579,P<0.001)是第1个疗程诱导疗效的唯一独立预后因素。 结论: AML患者诱导化疗后骨髓抑制期,采用MPFC检测骨髓MRD以2.305%为界能够预测诱导化疗疗效。.
引用
- Peng N, Wei H, Lin D, et al. [Prognostic significance of flow cytometric minimal residual disease in acute myeloid leukemia during aplasia]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29081193. doi:10.3760/cma.j.issn.0253-2727.2017.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。